A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years

Inclusion criteria

• Aged 4 to 17 years, inclusive:

• Cohort I: 12 to 17 years;
• Cohort II: 8 to 11 years;
• Cohort III: 4 to 7 years;
• Live in a region designated by the World Health Organization (WHO) as endemic for O. volvulus infection (World Health Organization, 2019). Specifically, participants will be recruited from the Kpassa sub-district of the Nkwanta North district.The specific communities will include Wii, Jagri-Do, and Azua where mass drug administration with ivermectin for onchocerciasis commenced in October 2017;
• Willing and able to remain at the study clinic from Screening up to Day 7;
• Provision of parental or guardian written informed consent and assent / lack of expression of 'deliberate objection' (as appropriate for age);
• Females of childbearing potential must commit to using a reliable method of contraception as per local family planning guidelines from Baseline (pre-treatment on Day 0) until approximately 6 months after treatment with study drug.

Exclusion criteria

• History of serious medical or psychiatric condition which, in the opinion of the investigator, would put the subject at increased risk by participating in the study or jeopardize study outcomes;
• Known or suspected concurrent clinically significant renal, cardiac, pulmonary, vascular, metabolic (thyroid disorders, adrenal disease), immunological disorders or malignancy, congenital heart disease, chronic lung disease;
• Has received an investigational product within 28 days or 5 half-lives of Baseline, whichever is longer;
• Has received ivermectin or any other anti-helminthic treatments within 28 days of Baseline;
• Has received a vaccination within 7 days of Baseline;
• Known or suspected hypersensitivity to macrocyclic lactones or excipients used in the formulation of moxidectin;
• Poor venous access;
• Unable to swallow tablets (flat oval, 8.0 millimeters (mm) x 4.5 mm x 3.0 mm);
• Weight:

• Cohort I (12 to 17 years): < 30 kg;
• Cohort II (8 to 11 years): < 18 kg;
• Cohort III (4 to 7 years): < 12 kg;
• Clinically relevant laboratory abnormalities at Screening, including:

• Hemoglobin < 9.5 grams per deciliter (g/dL);
• Neutrophil (granulocyte) count < 1.5 x 109/L;
• Platelet count < 110 x 109/L;
• Alanine aminotransferase (ALT) > 1.5 times the upper limit of normal range (ULN);
• Total bilirubin > 1.5 times ULN;
• Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV) positive;
• Known or suspected malaria or other ongoing viral, bacterial, or plasmodium infection at Screening and/or Baseline;
• Loa loa co-infection;
• Unwilling, unlikely or unable to comply with all protocol specified assessments;
• For females of child bearing potential, pregnant or breastfeeding, or planning to become pregnant;
• Previous enrolment in this study;
• Is a sibling of another child already enrolled in this study.